. Author manuscript; available in PMC: 2012 Sep 27.

Published in final edited form as: Am J Obstet Gynecol. 2009 Jun;200(6):595–609. doi: 10.1016/j.ajog.2009.04.005

TABLE 6.

Effect of magnesium sulfate on infant neurodevelopmental outcomes

Outcome	No of trials	Number of events/total number		Relative risk (95% Cl)	I²(%)
Outcome	No of trials	Magnesium	No magnesium	Relative risk (95% Cl)	I²(%)
Substantial gross motor dysfunction	3^31,34,35	56/2169	94/2218	0.60 (0.43–0.83)	0.0
Major neurologic disability	2^31,32	93/1033	85/1027	1.09(0.83–1.43)	15.3
Any neurological impairment	2^31,32	198/1033	194/1027	1.02(0.86–1.20)	0.0
Bayley mental development index <85	3^31,34,35	639/2169	660/2218	1.00(0.91–1.09)	0.0
Bayley mental development index <70	1³⁵	165/1188	171/1256	1.02(0.84–1.24)	NA
Bayley psychomotor development index <85	1³⁵	299/1188	315/1256	1.00(0.88–1.15)	NA
Bayley psychomotor development index <70	1³⁵	134/1188	144/1256	0.98(0.79–1.23)	NA
Blindness	2^31,34	2/981	2/962	0.97(0.14–6.90)	0.0
Deafness	2^31,34	8/981	11/962	0.51 (0.05–4.96)	58.7

Cl, confidence interval; NA, not; applicable